Receptors, TNF-Related Apoptosis-Inducing Ligand
"Receptors, TNF-Related Apoptosis-Inducing Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumor necrosis factor receptor family members that are widely expressed and play a role in regulation of peripheral immune responses and APOPTOSIS. The receptors are specific for TNF-RELATED APOPTOSIS-INDUCING LIGAND and signal via conserved DEATH DOMAINS that associate with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
| Descriptor ID |
D053220
|
| MeSH Number(s) |
D12.776.543.750.690.600 D12.776.543.750.705.852.760.396
|
| Concept/Terms |
Receptors, TNF-Related Apoptosis-Inducing Ligand- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, TNF Related Apoptosis Inducing Ligand
- Tumor Necrosis Factor Receptor Superfamily, Member 10
- TRAIL Receptors
- Receptors, TRAIL
- Receptors, Tumor Necrosis Factor, Member 10
- TNF-Related Apoptosis-Inducing Ligand Receptors
- TNF Related Apoptosis Inducing Ligand Receptors
Receptors, Tumor Necrosis Factor, Member 10d- Receptors, Tumor Necrosis Factor, Member 10d
- Decoy Receptor 2, Tumor Necrosis Factor
- Receptor, TRAIL-4
- Receptor, TRAIL 4
- TRAIL-4 Receptor
- DCR2 Receptor
- Receptor, DCR2
- CD264 Antigen
- Antigen, CD264
- TRAIL Receptor 4
- Receptor 4, TRAIL
Receptors, Tumor Necrosis Factor, Member 10a- Receptors, Tumor Necrosis Factor, Member 10a
- Tumor Necrosis Factor Receptor Superfamily, Member 10a
- APO2 Receptor
- Receptor, APO2
- Receptor, TRAIL-1
- Receptor, TRAIL 1
- TRAIL-1 Receptor
- TRAIL Receptor 1
- DR4 Receptor
- Receptor, DR4
- CD261 Antigen
- Antigen, CD261
- Death Receptor-4
- Death Receptor 4
- Receptor-4, Death
Receptors, Tumor Necrosis Factor, Member 10b- Receptors, Tumor Necrosis Factor, Member 10b
- TRAIL Receptor 2
- Receptor, TRAIL-2
- Receptor, TRAIL 2
- TRAIL-2 Receptor
- DR5 Receptor
- Receptor, DR5
- Tumor Necrosis Factor Receptor Superfamily, Member 10b
- TNF-Related Apoptosis-Inducing Ligand Receptor 2
- TNF Related Apoptosis Inducing Ligand Receptor 2
- CD262 Antigen
- Antigen, CD262
- Death Receptor-5
- Death Receptor 5
|
Below are MeSH descriptors whose meaning is more general than "Receptors, TNF-Related Apoptosis-Inducing Ligand".
Below are MeSH descriptors whose meaning is more specific than "Receptors, TNF-Related Apoptosis-Inducing Ligand".
This graph shows the total number of publications written about "Receptors, TNF-Related Apoptosis-Inducing Ligand" by people in this website by year, and whether "Receptors, TNF-Related Apoptosis-Inducing Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, TNF-Related Apoptosis-Inducing Ligand" by people in Profiles.
-
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clin Cancer Res. 2023 08 15; 29(16):2988-3003.
-
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).
-
Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 05; 20(5):524-532.
-
ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Mol Cancer Ther. 2017 07; 16(7):1290-1298.
-
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ. 2016 11 01; 23(11):1886-1896.
-
Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets. 2015; 19(9):1171-85.
-
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.
-
Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption. Mol Carcinog. 2015 Dec; 54(12):1796-806.
-
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200.
-
TRAIL death receptor 4 signaling via lysosome fusion and membrane raft clustering in coronary arterial endothelial cells: evidence from ASM knockout mice. J Mol Med (Berl). 2013 Jan; 91(1):25-36.